Colorised scanning electron micrograph of a cell heavily infected with SARS-CoV-2 virus particles (yellow). Credit: NIAID.

Moderna has started dosing participants in the Phase III clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

The study, named COVE, is being performed in alliance with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the randomised, placebo-controlled trial, a 100µg dose of the vaccine candidate will be assessed in around 30,000 participants in the US.

The primary endpoint will be the prevention of symptomatic Covid-19, while key secondary endpoints include the prevention of severe Covid-19 and infection by SARS-CoV-2, irrespective of symptomology.

Moderna said that the primary efficacy analysis of the trial will be event-driven and depend on the number of participants with symptomatic Covid-19.

An independent Data and Safety Monitoring Board will review the study results.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moderna CEO Stephane Bancel said: “We are pleased to have started the Phase III COVE study. We are grateful to the efforts of so many inside and outside the company to get us to this important milestone.

“We look forward to this trial demonstrating the potential of our vaccine to prevent Covid-19, so that we can defeat this pandemic.”

The company is working with contract research organisation PPD to conduct the COVE study. PPD supported the Phase II trial of the vaccine candidate, which completed the enrolment of 600 participants at eight sites within one month.

Moderna has chosen almost 100 sites with representative demography and is working with those sites to enrol volunteers at increased risk of Covid-19 infection.

An interim analysis of a Phase I trial assessing the Covid-19 vaccine candidate found the product to be generally safe and well-tolerated. The findings have been published in the New England Journal of Medicine.